Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von ADHS und anderen Entwicklungsstörungen

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

  • 8337 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung der ADHS im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Asherson P (2017) Drug treatment for ADHD reduce risk of substance use disorder. Am J Psychiatry 174(9):827–828

    Article  Google Scholar 

  • Ashock AH, Mizuno Y, Volkow ND et al (2017) Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine. A systematic review and meta-analysis. JAMA Psychiatry 74(5):511–519

    Article  Google Scholar 

  • Banaschewski T, Becker K, Döpfner M et al (2017) Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. Eine aktuelle Bestandsaufnahme. Dt Ärztebl 114(9):149–159

    Google Scholar 

  • Banaschewski T, Hohmann S, Millenet S et al (2018) Langfassung der interdiziplinären evidenz- und konsensbasierten (S3) Leitlinie „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter“. AWMF-Registernummer 028-045

    Google Scholar 

  • Buoli M, Serati M, Cahn W (2016) Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother 16(2):131–144

    Article  CAS  Google Scholar 

  • Chang Z, Quinn PD, Hur K et al (2017) Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 74(6):597–603

    Article  Google Scholar 

  • Conzelmann A, Müller S, Jans T et al (2019) Long-term cardiovascular safety of psychostimulants in children with attention deficit hyperactivity disorder. Int J Psychiatry Clin Pract 23(2):157–159

    Article  CAS  Google Scholar 

  • Cortese S, Moreira-Maia CR, StFleur D et al (2016) Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 173(1):34–43

    Article  Google Scholar 

  • Cortese S, Adamo N, Del Giovane C et al (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727–738

    Article  Google Scholar 

  • Dalsgaard S, Kvist AP, Leckman JF et al (2014) Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 24(6):302–310

    Article  Google Scholar 

  • Fekete S, Hiemke C, Gerlach M (2019) Dose-related concentrations of neuro-/psychoactive drugs expected in blood of children and adolescents. Ther Drug Monit. Online ahead of print

    Google Scholar 

  • Franke AG, Northoff R, Hildt E (2015) The case of pharmacological neuroenhancement: medical, judicial and ethical aspects from a German perspective. Pharmacopsychiatry 48(7):256–264

    Article  CAS  Google Scholar 

  • Hennissen L, Bakker MJ, Banaschewski T (2017) Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs 31(3):199–215

    Article  CAS  Google Scholar 

  • Jensen CM, Amdisen BL, Jørgensen KJ, Arnfred SM (2016) Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. Atten Defic Hyperact Disord 8:3–11

    Article  Google Scholar 

  • Ji N, Findling RL (2015) An update of pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry 28(2):91–101

    Article  Google Scholar 

  • Kratochvil C (2012) ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk. Am J Psychiatry 169(2):112–114

    Article  Google Scholar 

  • Krinzinger H, Hall CL, Groom MJ et al (2019) Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neurosci Biobehav Rev 107:945–968

    Article  CAS  Google Scholar 

  • Lam AP, Matthies S, Graf E et al (2019) Long-term effects of multimodal treatment on adult attention-deficit/hyperactivity disorder symptoms. Follow-up analysis of the COMPAS Trial. JAMA Netw Open 2(5):e194980

    Article  Google Scholar 

  • London EB, Yoo JH, Fethke ED et al (2020) The safety and effectiveness of high-dose propranolol as a treatment for challenging behaviors in individuals with autism spectrum disorders. J Clin Psychopharmacol 40(2):122–129

    Article  Google Scholar 

  • Lopez PL, Torrente FM, Ciapponi A et al (2018) Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010840.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  • Lu Y, Sjölander A, Cederlöf M et al (2017) Association between medication use and performance on higher education entrance tests in individuals with attention-deficit/hyperactivity disorder. JAMA Psychiatry 74(8):815–822

    Article  Google Scholar 

  • Matthijssen AM, Dietrich A, Bierens M et al (2019) Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomized placebo-controlled discontinuation study. Am J Psychiatry 176(9):754–762t

    Article  Google Scholar 

  • Moffitt TE, Houts R, Asherson P et al (2015) Is adult ADHD a childhood neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry 172(10):967–977

    Article  Google Scholar 

  • Ooi YP, Weng SJ, Kossowsky J et al (2017) Oxytocin and autism spectrum disorder: a systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry 50(1):5–13

    CAS  PubMed  Google Scholar 

  • Poissant H, Mendrek A, Talbot N et al (2019) Behavioral and cognitive impacts of mindfulness-based interventions on adults with attention-deficit hyperactivity disorder: a systematic review. Behav Neuro. https://doi.org/10.1155/2019/5682050

    Article  Google Scholar 

  • Roll SC, Hahn M (2015) Neue Studien zu ADHS im Erwachsenenalter. DNP 16(2):26–28

    Article  Google Scholar 

  • Ustun B, Adler LA, Rudin C et al (2017) The world health organization adult attention-deficit/Hyperactivtiy disorder self-report screening scale for DSM-5. JAMA Psychiatry 74(5):520–526

    Article  Google Scholar 

  • Waltereit R, Müller WE (2018) Weiterbildungs-Curriculum Psychopharmakologie/Pharmakotherapie. Teil 4: Psychopharmakologie und klinische Psychopharmakotherapie der Stimulanzien. Psychopharamkotherapie 25(4):199–207

    Google Scholar 

  • Xue J, Zhang Y, Huang Y (2019) A meta-analytic investigation of the impact of mindfulness-based interventions on ADHD symptoms. Medicine 98(23):e15957

    Article  Google Scholar 

  • Young Z, Moghaddam N, Tickle A (2016) The efficacy of cognitive behavioral therapy for adults with ADHD: a systematic review and meta-analysis of randomized controlled trials. J Atten Disord. https://doi.org/10.1177/1087054716664413

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nordhausen/Freiburg, Deutschland

    Prof. Dr. med. Philip Heiser

  2. Mainz, Deutschland

    Otto Benkert

Authors
  1. Prof. Dr. med. Philip Heiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Germany

    Otto Benkert

  2. Klinik für Psychiatrie und Psychotherapie, ehemals Universitäts-Klinikum München Campus Innenstadt, München, Germany

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Heiser, P., Benkert, O. (2021). Medikamente zur Behandlung von ADHS und anderen Entwicklungsstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61753-3_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61752-6

  • Online ISBN: 978-3-662-61753-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation